Abbott GmbH & Co. KG
Division of Abbott Laboratories Inc.
www.abbott.de
Latest From Abbott GmbH & Co. KG
Deal Statistics Quarterly, Q2 2001
In Vivo presents another installment of our quarterly review of dealmaking--in this case April 2001-June 2001. Our data comes from Windhover's Strategic Transactions Database. We include medical device financings by industry segment and by deal type; medical device M&A; diagnostic financings and alliances by product category; pharma and biotech alliances by technology segment; pharma and biotech alliances by deal type, and pharma and biotech financings by market segment and therapeutic category.
Serono's Global Ambitions
Serono, Europe's biggest biotechnology company, is nearly one hundred years old. Recently, the company has been on a quest to establish a public image quite different from that of a traditional, family-owned pharmaceutical group. Driving Serono into the public eye is Ernesto Bertarelli, who took the helm from his father in 1996. The structural changes he brought about provided the framework for modernization. But Serono still has to make its mark in the US, where the most important determinant of success will be the timing of its launch of Rebif, its multiple sclerosis drug.
Deal Statistics Quarterly, Nov 2000-Jan 2001
In Vivo presents another installment of our quarterly review of dealmaking--in this case November 2000-January 2001. Our data comes from Windhover's Strategic Transactions Database. We include medical device financings by industry segment and by deal type; medical device M&A; diagnostic financings and alliances by product category; pharma and biotech alliances by technology segment; pharma and biotech alliances by deal type, and pharma and biotech financings by market segment and therapeutic category.
Albany Molecular's Next Act
In the fast-growing chemistry services market, Albany Molecular has proven itself a steady and, in recent times, superlative performer. Albany Molecular is capitalizing on its growing revenue stream and strong market performance by building up chemistry capabilities to provide one-stop, albeit specialty, shopping. But the company's growth and above-average margins stem largely from its one major royalty deal, on Allegra--and the company has been spending its time on services, not on at-risk deals.Recent acquisitions position Albany Molecular to provide more proprietary technologies: the key is whether the company's management is willing to take the financial risk of deals in which it has to fund its own early development in order to win an important piece of a product's upside and thus boost it service-company margins.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Non-Specific
- Alias(es)
- Knoll AG
- Ownership
- Private
- Headquarters
-
Worldwide
-
Europe
-
Western Europe
-
Germany
-
Germany
-
Western Europe
-
Europe
- Parent & Subsidiaries
- Abbott Laboratories Inc.
- Senior Management
-
Harald Eistetter, Dir. Biotech Liaisons
Steven Koehler, VP, Fin. & Info. - Contact Info
-
Abbott GmbH & Co. KG
Phone: (49) 6122 580
Max-Planck-Ring 2
Wiesbaden-Delkenheim, 65205
Germany
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Abbott GmbH & Co. KG
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice